Top Premarket Decliners-March 2024-www.financetom.com

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Top Premarket Decliners

Nov 24, 2025 5:06 AM

07:53 AM EST, 11/24/2025 (MT Newswires) -- Waldencast ( WALD ) shares were nearly 14% lower pre-bell Monday after the company reported a drop in Q3 revenue and updated its annual outlook.

Novo Nordisk ( NVO ) stock was down 11% after the company said that semaglutide failed to meet its primary endpoint of reducing Alzheimer's progression in two phase 3 trials.

Mobile-health Network Solutions ( MNDR ) shares were 11% lower, paring Friday's rally.

Previous page： Qiagen Plans $300 Million Synthetic Share Repurchase Next page： Russian car sales seen declining to 1.4 mln units in 2025

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Qiagen Plans $300 Million Synthetic Share Repurchase

Jan 13, 2025

04:56 AM EST, 01/13/2025 (MT Newswires) -- Qiagen ( QGEN ) said Sunday it plans to return up to about $300 million to shareholders through a synthetic share repurchase that combines a direct capital repayment with a reverse stock split. The synthetic share repurchase will become effective on Jan. 28. This approach is designed to return cash to shareholders in...

Russian car sales seen declining to 1.4 mln units in 2025

Jan 13, 2025

MOSCOW, Jan 13 (Reuters) - The Association of European Businesses said on Monday that car sales in Russia in 2025 would decline by 15% to 1.4 million units. In November 2024, the AEB predicted that car sales in Russia would reach more than 1.6 million units in 2024. ...

Caribou Biosciences Starts Phase 1 Trial for Lupus Drug Candidate

Jan 13, 2025

04:47 AM EST, 01/13/2025 (MT Newswires) -- Caribou Biosciences ( CRBU ) said Sunday it initiated the phase 1 trial evaluating its experimental therapy, CB-010, in patients with lupus nephritis and extrarenal lupus. Additionally, the company said it expects to report data from a study of CB-010 to treat certain large B cell lymphoma patients in the first half of...

Merus, Biohaven Partner to Develop Bispecific Therapies for Cancers

Jan 13, 2025

04:49 AM EST, 01/13/2025 (MT Newswires) -- Merus (MRUS) and Biohaven ( BHVN ) said Sunday they are partnering to co-develop three bispecific therapies using Merus' Biclonics platform and Biohaven's ( BHVN ) technologies. Financial terms of the research collaboration and license agreement were not disclosed. The collaboration has the potential to significantly benefit patients across various cancer types through...